biostudies-literatureUnknown28(3)Garcia-Garcia HMTo determine (1) the medium-term effect of rosiglitazone and glipizide on intra-stent neointima hyperplasia, (2) restenosis pattern as assessed by intra-vascular ultrasound (IVUS) and quantitative coronary angiography (QCA) in patients with T2DM and coronary artery disease. A total of 462 patients with T2DM were randomized to rosiglitazone or glipizide for up to 18 months in the APPROACH trial, and had evaluable baseline and follow-up IVUS examinations. There was no significant difference in the size of plaque behind stent between the rosiglitazone and glipizide groups at 18 months among those treated with a bare metal stent (-5.6 mm(3) vs. 1.9 mm(3); P = 0.61) or with a drug-eluting stent (12.1 mm(3) vs. 5.5 mm(3); P = 0.09). Similarly, there was no significant difference in percentage inThe international journal of cardiovascular imaging455-65https://www.ebi.ac.uk/biostudies/studies/S-EPMC3326367biostudies-literatureEvaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).PMC3326367Miller DMHuang CSavage MFowler RSerruys PWAhmed IRatner REGarg SSaarinen KKolatkar NSFitzgerald PAftring RPMcMorn SKolatkar NCannon CRatner RShemanski LJahnke LLouridas BCarson PYoung SJones PRussell RMorocutti GLachin JGerstein HAPPROACH study groupNesto RWChou HOlivieria TAbrahamson MGarcia-Garcia HMVan Es GAMiller DBrugaletta SMattioli DNesto RKravitz BGHoffman JSteele-Norwood DMintz GZalewski ASerruys PNguyen CKirsch CSlee AWeitz HWolstenholme AKravitz BfalseEvaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).To determine (1) the medium-term effect of rosiglitazone and glipizide on intra-stent neointima hyperplasia, (2) restenosis pattern as assessed by intra-vascular ultrasound (IVUS) and quantitative coronary angiography (QCA) in patients with T2DM and coronary artery disease. A total of 462 patients with T2DM were randomized to rosiglitazone or glipizide for up to 18 months in the APPROACH trial, and had evaluable baseline and follow-up IVUS examinations. There was no significant difference in the size of plaque behind stent between the rosiglitazone and glipizide groups at 18 months among those treated with a bare metal stent (-5.6 mm(3) vs. 1.9 mm(3); P = 0.61) or with a drug-eluting stent (12.1 mm(3) vs. 5.5 mm(3); P = 0.09). Similarly, there was no significant difference in percentage in2012-01-01T00:00:00Z2012 Mar2025-04-04T09:47:37.19Z2019-03-27T00:52:18ZS-EPMC33263672135983410.1007/s10554-011-9836-z